Clinical Trial

Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort (the REalCHALLENGE Study)

Study acronym: RealCHALLENGE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an observational, retrospective, international and multicenter study funded by Fondazione Oncologia Niguarda ETS to assess the efficacy of anti-EGFR rechallenge regimens in the largest real-world cohort of MSS mCRC patients screened for RAS/BRAF/PIK3CA ctDNA status on liquid biopsy within the MEN1611-02 C-PRECISE-01 trial. The study will collect molecular, clinical and outcome data of patients already available at participating centers.
Trial Details
NCT Number NCT07536113
Lead Sponsor Niguarda Hospital
Conditions Metastatic Colorectal Cancer (CRC)
Enrollment 250 participants
Start Date 2024-03-01
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-17